A Phase 3 interventional study of Symbicort Turbuhaler and Terbutaline Turbuhaler in Asthma, sponsored by AstraZeneca. Completed at 109 sites in 12 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2012-11-30.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 359 studies in Asthma by AstraZeneca — 19 open to participants now, 28 under way, 8 of them phase 3. Asthma · AstraZeneca.
Among the 359 studies in Asthma by AstraZeneca, this one is the 13th largest by enrollment of the 248 interventional ones that give a count, is one of 16 that started in 2009, is one of 121 in phase 3, and was the 120th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →19 of the 359 studies in Asthma by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Korea, Republic of
AstraZeneca · Sites in China
AstraZeneca · Sites in United States, Argentina, Austria and 11 more countries
Ages 6+
AstraZeneca · Sites in China
Ages 18–75
AstraZeneca · Sites in United States, Argentina, Czechia and 4 more countries
Ages 4–11
By country, each count listing its studies:
Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
359 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 46 · Phase 2 52 · Phase 3 123 · Phase 4 23
First in 1996; this study’s year is marked. 16 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,091 is above the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 175 across the 248 interventional studies, 500 across the 110 observational. Of the 330 that completed or were terminated, 129 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
13 of the studies in Asthma by AstraZeneca that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT06473779Phase 3AstraZenecaOpen-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. | 2027-06-25 |
| NCT06471257Phase 3AstraZenecaA Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma | 2027-10-04 |
| NCT06307665Phase 3AstraZenecaEvaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma | 2027-10-13 |
| NCT07218172AstraZenecaCharacterization and Clinical Outcomes of Severe Asthma Patients in Israel Treated With Benralizumab (SAIL-B) | 2026-11-30 |
Add all 13 to your calendar (.ics) → With an account.
Among the 359 studies in Asthma by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to compare the efficacy of Symbicort SMART (Symbicort Turbuhaler 160/4.5μg, one inhalation twice daily plus as needed) with Symbicort Turbuhaler 160/4.5μg, one inhalation twice daily plus terbutaline Turbuhaler 0.4 mg as needed, as asthma therapy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Symbicort Turbuhaler 160/4.5 µg one inhalation bid (twice daily) + Symbicort Turbuhaler 160/4.5 µg as needed
Drug: Symbicort Turbuhaler
Symbicort Turbuhaler 160/4.5 µg one inhalation bid (twice daily) + terbutaline Turbuhaler 0.4 mg as needed
Drug: Symbicort Turbuhaler · Drug: Terbutaline Turbuhaler
160/4.5 µg
0.4 mg
The Percentage of Participants Who Had Experienced Asthma Exacerbation(s) at the End of the Study
Asthma exacerbation was defined as deterioration in asthma leading to oral glucocorticosteroid \[GCS\] treatment, hospitalization, or emergency room \[ER\] treatment.
Time frame: week 52
Number of Asthma Exacerbations
Asthma exacerbation was defined as deterioration in asthma leading to oral GCS treatment, hospitalization, or ER treatment. Number of asthma exacerbations during 52 weeks treatment was presented here.
Time frame: up to 52 weeks
Morning Peak Expiratory Flow (PEF)
The mean value from a 52-week treatment period.
Time frame: 52-week treatment period
Evening PEF
The mean value from a 52-week treatment period.
Time frame: 2-week run-in period (14 - 18 days before randomization - week 0) and a 52-week treatment period
Forced Expiratory Volume in One Second (FEV1)
The mean value for Weeks 4, 12, 24, 36 and 52 was analysed.
Time frame: 4, 12, 24, 36 and 52 weeks after randomization
Use of As-needed Medication
The mean value of total daily number of inhalations from the treatment period for use of as-needed medication (daytime, night-time).
Time frame: 52-week treatment period
Asthma Symptom Score
The mean value from the treatment period for Total Asthma Symptom Score (total score: 0 is best - no asthma symptoms; 6 is worst).
Time frame: 52-week treatment period
Nights With Awakening(s) Due to Asthma Symptoms
The mean value from the treatment period was presented here.
Time frame: 52-week treatment period
The Percentage of Participants Who Had Experienced First Mild Asthma Exacerbations
Mild asthma exacerbation was defined as morning PEF ≥20% below baseline, daily as-needed medication use ≥2 inhalations above baseline, or a night with awakening due to asthma symptoms. The percentage of participants who had experienced mild asthma exacerbation(s) at the end of the study was presented here.
Time frame: up to 52 weeks
Symptom-free Days (no Symptoms and no Awakenings)
A symptom-free day was defined as a day without daytime or night-time symptoms and without night-time awakenings due to asthma symptoms. The mean value was presented here.
Time frame: 52-week treatment period
Percentage of As-needed-free Days
An as-needed-free day is defined as a night and day with no use of as-needed medication. The mean value from the treatment period was presented here.
Time frame: 52-week treatment period
Percentage of Asthma-control Days (no Asthma Symptoms, no Awakenings, and no As-needed Use)
An asthma-control day was defined as a a night and day with no asthma symptoms, no awakenings due to asthma symptoms, and no as-needed medication use. The mean value from the treatment period was presented here.
Time frame: 52-week treatment period
Asthma Control Questionnaire (ACQ)
The ACQ developed by Juniper and colleagues (Juniper et al 1999) was used without the FEV1 and Beta 2-agonist questions. The Asthma Control Questionnaire has 5 questions that are assessed on a 7-point scale from 0 to 6 where 0 represents good control and 6 represents poor control. The overall score is the mean of the five responses. At least 4 out of the 5 questions must have been answered to provide a value. The mean of the overall score for Weeks 4 to 52 was presented here.
Time frame: 4, 12, 24, 36 and 52 weeks after randomization
The first participant entered the study on 16 February 2009, and the last participant completed the study on 23 February 2011. A total of 3209 participants were enrolled at 148 centres in 13 countries in Asia, America and Europe, and 2091 participants who fulfilled the randomisation criteria were randomised.
| Milestone | Symbicort SMART | Symbicort+Terbutaline As Needed |
|---|---|---|
| Started | 1049 | 1042 |
| Completed | 956 | 932 |
| Not completed | 93 | 110 |
| Withdrew: Adverse event | 8 | 12 |
| Withdrew: Lost to follow-up | 31 | 26 |
| Withdrew: Withdrawal by subject | 28 | 34 |
| Withdrew: Incorrect enrolment | 3 | 3 |
| Withdrew: Study-specific discontinuation criteria | 6 | 13 |
| Withdrew: Safety reasons | 2 | 1 |
| Withdrew: Other | 8 | 14 |
| Withdrew: Severe non-compliance to protocol | 7 | 7 |
Asthma exacerbation was defined as deterioration in asthma leading to oral glucocorticosteroid \[GCS\] treatment, hospitalization, or emergency room \[ER\] treatment.
| percentage of participants | Symbicort SMART | Symbicort+Terbutaline As Needed |
|---|---|---|
| The Percentage of Participants Who Had Experienced Asthma Exacerbation(s) at the End of the Study | 16 | 22 |
Asthma exacerbation was defined as deterioration in asthma leading to oral GCS treatment, hospitalization, or ER treatment. Number of asthma exacerbations during 52 weeks treatment was presented here.
| Asthma exacerbations | Symbicort SMART | Symbicort+Terbutaline As Needed |
|---|---|---|
| Number of Asthma Exacerbations | 259 | 363 |
The mean value from a 52-week treatment period.
| Liter/minute (L/min) | Symbicort SMART | Symbicort+Terbutaline As Needed |
|---|---|---|
| Morning Peak Expiratory Flow (PEF) | 331.8 ± 102.2 | 324.7 ± 101.9 |
The mean value from a 52-week treatment period.
| L/min | Symbicort SMART | Symbicort+Terbutaline As Needed |
|---|---|---|
| Evening PEF | 334.2 ± 102.6 | 327.8 ± 103.1 |
The mean value for Weeks 4, 12, 24, 36 and 52 was analysed.
| Liter (L) | Symbicort SMART | Symbicort+Terbutaline As Needed |
|---|---|---|
| Forced Expiratory Volume in One Second (FEV1) | 2.258 ± 0.76 | 2.222 ± 0.77 |
The mean value of total daily number of inhalations from the treatment period for use of as-needed medication (daytime, night-time).
| inhalations/day | Symbicort SMART | Symbicort+Terbutaline As Needed |
|---|---|---|
| Use of As-needed Medication | 1.21 ± 1.39 | 1.46 ± 1.60 |
The mean value from the treatment period for Total Asthma Symptom Score (total score: 0 is best - no asthma symptoms; 6 is worst).
| units on a scale | Symbicort SMART | Symbicort+Terbutaline As Needed |
|---|---|---|
| Asthma Symptom Score | 1.12 ± 1.04 | 1.22 ± 1.02 |
The mean value from the treatment period was presented here.
| Nights With Awakening(s) | Symbicort SMART | Symbicort+Terbutaline As Needed |
|---|---|---|
| Nights With Awakening(s) Due to Asthma Symptoms | 15.7 ± 27.1 | 17.5 ± 27.2 |
Mild asthma exacerbation was defined as morning PEF ≥20% below baseline, daily as-needed medication use ≥2 inhalations above baseline, or a night with awakening due to asthma symptoms. The percentage of participants who had experienced mild asthma exacerbation(s) at the end of the study was presented here.
| percentage of participants | Symbicort SMART | Symbicort+Terbutaline As Needed |
|---|---|---|
| The Percentage of Participants Who Had Experienced First Mild Asthma Exacerbations | 71 | 80 |
A symptom-free day was defined as a day without daytime or night-time symptoms and without night-time awakenings due to asthma symptoms. The mean value was presented here.
| symptom-free days | Symbicort SMART | Symbicort+Terbutaline As Needed |
|---|---|---|
| Symptom-free Days (no Symptoms and no Awakenings) | 45.5 ± 37.8 | 41.6 ± 37.2 |
An as-needed-free day is defined as a night and day with no use of as-needed medication. The mean value from the treatment period was presented here.
| percentage of as-needed-free days | Symbicort SMART | Symbicort+Terbutaline As Needed |
|---|---|---|
| Percentage of As-needed-free Days | 51.4 ± 36.7 | 47.2 ± 36.7 |
An asthma-control day was defined as a a night and day with no asthma symptoms, no awakenings due to asthma symptoms, and no as-needed medication use. The mean value from the treatment period was presented here.
| percentage of asthma-control days | Symbicort SMART | Symbicort+Terbutaline As Needed |
|---|---|---|
| Percentage of Asthma-control Days (no Asthma Symptoms, no Awakenings, and no As-needed Use) | 41.7 ± 37.3 | 37.9 ± 36.6 |
The ACQ developed by Juniper and colleagues (Juniper et al 1999) was used without the FEV1 and Beta 2-agonist questions. The Asthma Control Questionnaire has 5 questions that are assessed on a 7-point scale from 0 to 6 where 0 represents good control and 6 represents poor control. The overall score is the mean of the five responses. At least 4 out of the 5 questions must have been answered to provide a value. The mean of the overall score for Weeks 4 to 52 was presented here.
| units on a scale | Symbicort SMART | Symbicort+Terbutaline As Needed |
|---|---|---|
| Asthma Control Questionnaire (ACQ) | 1.162 ± 0.78 | 1.289 ± 0.75 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Symbicort SMART | — | 41/1,049 (3.9%) | 279/1,049 (26.6%) |
| Symbicort+Terbutaline As Needed | — | 74/1,042 (7.1%) | 293/1,042 (28.1%) |
| Event | Symbicort SMART | Symbicort+Terbutaline As Needed |
|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 5/1049 | 31/1042 |
| PneumoniaInfections and infestations | 4/1049 | 2/1042 |
| GastroenteritisInfections and infestations | 1/1049 | 3/1042 |
| Abdominal PainGastrointestinal disorders | 3/1049 | 0/1042 |
| Traumatic Brain InjuryInjury, poisoning and procedural complications | 0/1049 | 2/1042 |
| Type 2 Diabetes MellitusMetabolism and nutrition disorders | 0/1049 | 2/1042 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/1049 | 2/1042 |
| TracheobronchitisInfections and infestations | 2/1049 | 0/1042 |
| Upper Respiratory Tract Infection BacterialInfections and infestations | 2/1049 | 0/1042 |
| Uterine LeiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/1049 | 0/1042 |
| Event | Symbicort SMART | Symbicort+Terbutaline As Needed |
|---|---|---|
| NasopharyngitisInfections and infestations | 137/1049 | 133/1042 |
| BronchitisInfections and infestations | 69/1049 | 77/1042 |
| Viral Upper Respiratory Tract InfectionInfections and infestations | 60/1049 | 72/1042 |
| PharyngitisInfections and infestations | 49/1049 | 58/1042 |
| Age Continuous(years) | Symbicort SMART | Symbicort+Terbutaline As Needed | Total |
|---|---|---|---|
| Mean | 45.7 (16 to 84) | 45.6 (16 to 85) | 45.7 (16 to 85) |
| Sex: Female, Male(Participants) | Symbicort SMART | Symbicort+Terbutaline As Needed | Total |
|---|---|---|---|
| Female | 722 | 692 | 1414 |
| Male | 327 | 350 | 677 |
Showing the first 100 of 109 sites across 12 countries. Choose a country and city above to see the rest.
The record gives a start of Feb 2009, a primary completion of Feb 2011 and a completion of Feb 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2012, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Budesonide/Formoterol Fumarate Dihydrate Inhalation Aerosol